GOFAXDII Trademark

Trademark Overview


On Monday, January 30, 2023, a trademark application was filed for GOFAXDII with the United States Patent and Trademark Office. The USPTO has given the GOFAXDII trademark a serial number of 97772587. The federal status of this trademark filing is REGISTERED as of Tuesday, September 10, 2024. This trademark is owned by CSL Behring GmbH. The GOFAXDII trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for treating von Willebrand disease, hemophilia, primary immunodeficiency, hereditary angioedema, fibrinogen deficiency, Alpha 1 antitrypsin deficiency, and inflammatory demyelinating polyneuropathy; blood plasma; blood plasma fractions; recombinant protein arrays for medical diagnosis purposes; Pharmaceutical preparations for the treatment and prevention of blood and bleeding disorders; blood products for the treatment of hemophilia, namely, pharmaceutical preparations for the treatment of hemophilia; pharmaceutical products derived from recombinant DNA technology for the treatment of hemophilia, namely, pharmaceutical preparations derived from recombinant DNA technology for the treatment of hemophilia; blood products for the treatment of hemophilia, namely, a blood clotting aid and delivery system for use in human and veterinary medicine; pharmaceutical preparations and substances for the treatment of blood disorders; antibodies, namely, diagnostic kits co...
gofaxdii

General Information


Serial Number97772587
Word MarkGOFAXDII
Filing DateMonday, January 30, 2023
Status700 - REGISTERED
Status DateTuesday, September 10, 2024
Registration Number7498482
Registration DateTuesday, September 10, 2024
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, June 25, 2024

Trademark Statements


Goods and ServicesPharmaceutical preparations for treating von Willebrand disease, hemophilia, primary immunodeficiency, hereditary angioedema, fibrinogen deficiency, Alpha 1 antitrypsin deficiency, and inflammatory demyelinating polyneuropathy; blood plasma; blood plasma fractions; recombinant protein arrays for medical diagnosis purposes; Pharmaceutical preparations for the treatment and prevention of blood and bleeding disorders; blood products for the treatment of hemophilia, namely, pharmaceutical preparations for the treatment of hemophilia; pharmaceutical products derived from recombinant DNA technology for the treatment of hemophilia, namely, pharmaceutical preparations derived from recombinant DNA technology for the treatment of hemophilia; blood products for the treatment of hemophilia, namely, a blood clotting aid and delivery system for use in human and veterinary medicine; pharmaceutical preparations and substances for the treatment of blood disorders; antibodies, namely, diagnostic kits consisting primarily of monoclonal antibodies, buffers, and reagents for use in disease testing; blood for medical purposes; cell cultures for medical purposes, namely, cells for medical or clinical use; cell cultures for medical purposes, namely, living cells for medical use; cell cultures for medical purposes, namely, stem cells for medical or veterinary use; pharmaceutical preparations for the treatment of blood conditions, respiratory conditions, pneumonia, covid-19, and influenza; Pharmaceutical preparations, namely, antibody for the treatment of acute respiratory distress syndrome, ARDS; pharmaceutical preparations, namely, antibody for the treatment of Idiopathic Pulmonary Fibrosis, IPF and Interstitial Lung Diseases, ILD; Pharmaceutical preparations, namely, antibody for the treatment of Hereditary Angioedema, HAE

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateThursday, February 16, 2023
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameCSL Behring GmbH
Party Type30 - Original Registrant
Legal Entity Type16 - Limited Liability Company
AddressMarburg D-35041
DE

Party NameCSL Behring GmbH
Party Type20 - Owner at Publication
Legal Entity Type16 - Limited Liability Company
AddressMarburg D-35041
DE

Party NameCSL Behring GmbH
Party Type10 - Original Applicant
Legal Entity Type16 - Limited Liability Company
AddressMarburg D-35041
DE

Trademark Events


Event DateEvent Description
Thursday, February 2, 2023NEW APPLICATION ENTERED
Thursday, February 16, 2023NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Friday, October 27, 2023ASSIGNED TO EXAMINER
Monday, April 29, 2024NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
Monday, April 29, 2024SUSPENSION INQUIRY WRITTEN
Monday, April 29, 2024INQUIRY TO SUSPENSION E-MAILED
Friday, May 10, 2024CORRESPONDENCE RECEIVED IN LAW OFFICE
Friday, May 10, 2024TEAS/EMAIL CORRESPONDENCE ENTERED
Friday, May 10, 2024TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
Thursday, May 23, 2024APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, June 5, 2024NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, June 25, 2024PUBLISHED FOR OPPOSITION
Tuesday, June 25, 2024OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, September 10, 2024REGISTERED-PRINCIPAL REGISTER
Tuesday, September 10, 2024NOTICE OF REGISTRATION CONFIRMATION EMAILED
Friday, October 27, 2023NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Friday, October 27, 2023SUSPENSION LETTER WRITTEN
Friday, October 27, 2023LETTER OF SUSPENSION E-MAILED